Article Text

PDF
GI highlights from the literature
  1. Guruprasad P Aithal, JournanScan Editor
  1. Correspondence to Dr Guruprasad P Aithal, Nottingham Digestive Disease Centre: Biomedical Research Unit, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK; guru.aithal{at}nuh.nhs.uk

Statistics from Altmetric.com

Sleeping with the enemy

▶ Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627–36.

Angiotensin-receptor blockers (ARBs) are a widely used drug class approved for treatment of hypertension, heart failure, diabetic nephropathy and, recently, for cardiovascular risk reduction. Animal experimental studies implicate the renin–angiotensin system in hepatic myofibroblasts as a powerful stimulator of fibrosis. Hence, randomised clinical trials are underway to investigate the efficacy of ARBs in non-alcoholic fatty liver disease and portal hypertension. However, angiotensin II type 1 and type 2 receptors, in particular, are also involved in the regulation of cell proliferation, angiogenesis and tumour progression.

Sipahi et al assessed whether ARBs affect cancer occurrence with a meta-analysis of randomised controlled trials of these drugs. Randomised controlled trials with a follow-up of at least 1 year, which enrolled at least 100 patients were included. Authors found that the patients assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with the control groups (7.2% vs 6.0%, RR=1.08, 95% CI 1.01 to 1.15; p=0.016). When analysis was limited to trials where cancer was a pre-specified end point, the RR was 1.11 (95% …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.